These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 24384695)
1. Psychiatrists' perspectives on antipsychotic dose and the role of plasma concentration therapeutic drug monitoring. Best-Shaw L; Gudbrandsen M; Nagar J; Rose D; David AS; Patel MX Ther Drug Monit; 2014 Aug; 36(4):486-93. PubMed ID: 24384695 [TBL] [Abstract][Full Text] [Related]
2. The European psychiatric association (EPA) - early career psychiatrists committee survey on trainees' and early-career psychiatrists' attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment. Schoretsanitis G; Correll CU; Agorastos A; Compaired Sanchez A; Erzin G; Grigoras RM; Grizelj Benussi M; Gondek TM; Guloksuz S; Højlund M; Jerotic S; Kilic O; Metaj E; Sidhu DS; Skandali N; Skuhareuski A; Tveito M; Wolthusen RPF; ; Chumakov E; de Filippis R World J Biol Psychiatry; 2024 Jul; 25(6):342-351. PubMed ID: 38905131 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotic polypharmacy in schizophrenia: benefits and risks. Barnes TR; Paton C CNS Drugs; 2011 May; 25(5):383-99. PubMed ID: 21476610 [TBL] [Abstract][Full Text] [Related]
9. Psychiatrists' Attitude and Use of Second-generation Antipsychotics for the Treatment of Schizophrenia in Taiwan. Chen CK; Su HH; Sun IW East Asian Arch Psychiatry; 2017 Sep; 27(3):91-6. PubMed ID: 28993541 [TBL] [Abstract][Full Text] [Related]
10. Attitudes of Croatian psychiatrists towards long-acting injectable antipsychotics. Ciglar M; Bjedov S; Maleković H Psychiatr Danub; 2016 Sep; 28(3):273-277. PubMed ID: 27658836 [TBL] [Abstract][Full Text] [Related]
11. Barriers to long-acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey. Oguchi Y; Miyake N; Ando K Neuropsychopharmacol Rep; 2024 Jun; 44(2):417-423. PubMed ID: 38634351 [TBL] [Abstract][Full Text] [Related]
12. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. Schoretsanitis G; Kane JM; Correll CU; Marder SR; Citrome L; Newcomer JW; Robinson DG; Goff DC; Kelly DL; Freudenreich O; Piacentino D; Paulzen M; Conca A; Zernig G; Haen E; Baumann P; Hiemke C; Gründer G; ; Pharmakopsychiatrie TTDMTFOTAFNU J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433836 [TBL] [Abstract][Full Text] [Related]
13. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883 [TBL] [Abstract][Full Text] [Related]
14. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India. Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143 [TBL] [Abstract][Full Text] [Related]
15. Factors Influencing the Use of Second-Generation Antipsychotics in Children with Psychosis. Ramachandran S; Banahan BF; Bentley JP; West-Strum DS; Patel AS J Manag Care Spec Pharm; 2016 Aug; 22(8):948-57. PubMed ID: 27459658 [TBL] [Abstract][Full Text] [Related]
16. Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia. Sugawara N; Yasui-Furukori N; Yamazaki M; Shimoda K; Mori T; Sugai T; Suzuki Y; Someya T PLoS One; 2014; 9(1):e86826. PubMed ID: 24466260 [TBL] [Abstract][Full Text] [Related]
17. Psychiatrists' opinion towards medication discontinuation in remitted first-episode psychosis: A multi-site study of the Asian Network for Early Psychosis. Hui CL; Wong AK; Leung WW; Lee EH; Chan SK; Chang WC; Chen EY; Chan TC; Swapna V; Tagata H; Tsujino N; Nemoto T; Mizuno M; Kang NI; Kim SW; Chung YC Early Interv Psychiatry; 2019 Dec; 13(6):1329-1337. PubMed ID: 30485671 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of atypical antipsychotic drugs. Grundmann M; Kacirova I; Urinovska R Acta Pharm; 2014 Dec; 64(4):387-401. PubMed ID: 25531781 [TBL] [Abstract][Full Text] [Related]
19. The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load. Nguyen ML; Sunderland B; Lim S; Hattingh L; Chalmers L Int J Clin Pharm; 2019 Dec; 41(6):1642-1651. PubMed ID: 31677120 [TBL] [Abstract][Full Text] [Related]
20. How do psychiatrists choose among different antipsychotics? Hamann J; Kolbe G; Cohen R; Leucht S; Kissling W Eur J Clin Pharmacol; 2005 Dec; 61(11):851-4. PubMed ID: 16235042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]